INCA-036873

N/A

Report date: 2026/04/10 20:01:49

First In Class

Base Information

Drug NameINCA-036873

Drug Alias NameINCA036873INCA-036873

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-CD70Anti-CD3

TargetsCD70 antigenT cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumoursHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited StatesItaly +[5]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesIncyte Corp

China Registration ClassN/A

Develop Information

Active CompaniesIncyte Corp

Inactive CompaniesN/A

Active IndicationsSolid tumoursHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A